Loading patent…
AssigneeGlycoEra AG
InventorsGanesh Venkataraman Kaundinya, Tanmoy Chinmoy Ganguly, Rainer Follador, Manuela Mally, Jonathan Albert Back, Michela Manni
Estimating the term…
Provided herein are glycoengineered polypeptides comprising a first moiety comprising one or more peptides that specifically binds to a target antibody (e.g., an IgA1 or an immune complex comprising the same, a gd-IgA1 or an immune complex comprising the same, or an anti-gd-IgA1 autoantibody or an immune complex comprising the same) and a second moiety comprising one or more glycans conjugated to the first moiety at one or more glycosylation sites. Also provided herein are nucleic acid sequence encoding provided glycoengineered polypeptides. Further provided herein are compositions comprising glycoengineered polypeptides and/or nucleic acids encoding the same, as well as methods of making and using the same.
A glycoengineered polypeptide comprising:
The glycoengineered polypeptide of any one of the preceding claims, wherein the one or more glycans comprise a terminal GlcNac, a terminal GalNac, or a terminal Gal.
The glycoengineered polypeptide of any one of the preceding claims, wherein the one or more glycans is an N-glycan, optionally wherein the N-glycan is linked to the first moiety of the glycoengineered polypeptide at 1, 2, 3, 4 or 5 N-glycosylation sites.
The glycoengineered polypeptide of any one of the preceding claims, wherein the one or more glycans comprise a glycan structure comprising GlcNAc2-Man3-GlcNAc2, GalNAc2-GlcNAc2-Man3-GlcNAc2, Gal2-GlcNAc2-Man3-GlcNAc2, GlcNAc1-Man3-GlcNAc2, Gal2-GlcNAc2-Man3-GlcNAc2, Gal1-GlcNAc2-Man3-GlcNAc2, GalNAc1-GlcNAc2-Man3-GlcNAc2, GlcNAc3-Man3-GlcNAc2, GlcNAc4-Man3-GlcNAc2, Gal3-GlcNAc3-Man3-GlcNAc2, GalNAc3-GlcNAc3-Man3-GlcNAc2, GalNAc4-GlcNAc4-Man3-GlcNAc2, Gal4-GlcNAc4-Man3-GlcNAc2, or Man-6-P-N-glycan.
The glycoengineered polypeptide of any one of the preceding claims, wherein the first moiety comprises one or more peptides that specifically bind to a glycosylation-deficient IgA1 (gd-IgA1), or a fragment or a complex thereof, optionally wherein the gd-IgA1 comprises a hinge region that is glycosylated.
The glycoengineered polypeptide of any one of the preceding claims, wherein the first moiety comprises:
The glycoengineered polypeptide of any one of the preceding claims, wherein the polypeptide comprises one or more additional elements chosen from:
The glycoengineered polypeptide of any one of the preceding claims, wherein the second moiety is conjugated to the first moiety in vivo.
A polynucleotide encoding the glycoengineered polypeptide of any one of the preceding claims.
Dependencies are inferred from the claim text.